vcr 170 +7 +4.3% - holding up well, page-30

re: the most overvalued stock on asx. and here's what they said syringe:
Quote:
"The unfortunate thing is 2004 and 2005 were going to be Thoratec's best years because it had a functional monopoly on destination therapy," says Lazard's Arrow, "while all of its competitors are still only good for bridge-to-transplant therapy. If there were ever going to be two great years in the history of Thoratec, it would be 2004 and 2005. But now it looks like it will take two years for attitudes to change sufficiently for cardiologists to recommend patients to get destination therapy. And by 2006, all the competition will come out with new products, and they will probably be superior to Thoratec's because they will be smaller, last longer and be more mechanically reliable." (Arrow doesn't own shares of Thoratec; Lazard has an investment-banking relationship with the company.)

from
http://yahoo.smartmoney.com/onedaywonder/index.cfm?story=20040630&afl=yahoo

so thoratec are the ones you should be shorting- crappy second generation lvads like they are researching are a dead end.......